Inhibition of IgE production by epsilon (epsilon) chain-specific antisense oligonucleotides (AOs) studied on human myeloma cell line U266 and peripheral blood mononuclear cells of a patient with hypereosinophilia.

[1]  D. Wielbo,et al.  Inhibition of hypertension by peripheral administration of antisense oligodeoxynucleotides. , 1996, Hypertension.

[2]  H. Ha,et al.  Roles of protein phosphatase 1 and 2A in an IL-6-mediated autocrine growth loop of human myeloma cells. , 1996, Cellular Immunology.

[3]  J. Isner,et al.  Processing of chimeric antisense oligonucleotides by human vascular smooth muscle cells and human atherosclerotic plaque. Implications for antisense therapy of restenosis after angioplasty. , 1996, Circulation.

[4]  A. Wilks,et al.  Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. , 1996, Cancer research.

[5]  K. Koike,et al.  In vivo inhibition of hepatitis B virus gene expression by antisense phosphorothioate oligonucleotides. , 1996, Biochemical and biophysical research communications.

[6]  K. Kajiwara,et al.  Inhibition of IL‐4 receptor up‐regulation on B cells by antisense oligodeoxynucleotide suppresses IL‐4‐induced human IgE production , 1995, Clinical and experimental immunology.

[7]  D. Welch,et al.  Enhanced metastatic ability of TNF-alpha-treated malignant melanoma cells is reduced by intercellular adhesion molecule-1 (ICAM-1, CD54) antisense oligonucleotides. , 1994, Experimental cell research.

[8]  A. Szabolcs,et al.  Base-modified oligodeoxynucleotides. I. effect of 5-alkyl, 5-(1-alkenyl) and 5-(1-alkynyl) substitution of the pyrimidines on duplex stability and hydrophobicity , 1993 .

[9]  J. Brostoff,et al.  Specific inhibition of IgE antibody production by an antisense oligodeoxynucleotide oligomer (Oligostick). , 1992, Immunology.

[10]  D. Stanworth,et al.  Allergy treatment with a peptide vaccine , 1990, The Lancet.

[11]  T. Ishizaka,et al.  Expression of a biologically active fragment of human IgE epsilon chain in Escherichia coli. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[12]  K. Blaser,et al.  Effect of passively administered isologous anti-idiotypes directed against anti-carrier (ovalbumin) antibodies on the anti-hapten IgE and IgG antibody responses in BALB/c mice. , 1983, Immunology.

[13]  T. Honjo,et al.  Molecular cloning and nucleotide sequencing of human immunoglobulin € chain cDNA , 1983 .

[14]  J. Flanagan,et al.  The sequence of a human immunoglobulin epsilon heavy chain constant region gene, and evidence for three non‐allelic genes. , 1982, The EMBO journal.

[15]  M. Stearns,et al.  Cytokine (IL-10, IL-6) induction of tissue inhibitor of metalloproteinase 1 in primary human prostate tumor cell lines. , 1995, Oncology research.

[16]  G. Sczakiel.  Antisense strategies in the treatment of hematological malignancies , 1995, Stem cells.

[17]  M. Guenounou,et al.  Immunomodulation by cytokine antisense oligonucleotides. , 1995, European cytokine network.

[18]  J. Szécsi,et al.  First synthesis of carbocyclic oligothymidylates , 1990 .

[19]  F-T. Lui.  Expression of a biologically active fragment of human IgE ε chain in Escherichia coli , 1984 .

[20]  A. Sehon.  Suppression of IgE antibody responses with tolerogenic conjugates of allergens and haptens. , 1982, Progress in allergy.